Dengue virus, a life-debilitating, potentially deadly mosquito-borne virus that infects 400 million people, hospitalizes 1.5 million and kills 100,000+ annually
Ennaid Therapeutics is using its unique platform technology of flavivirus fusion inhibitors to develop cures for all four strains of Dengue virus.
We welcome strategic partnerships, as partnerships accelerate the development of our cures from the lab to the people who need them.
CEO and President
VP, International Business Development
Scientific Advisory Board
Chief Scientific Officer, Inventor & Board of Directors